Menopause
Conditions
Brief summary
The purpose of this study is to find out if a novel drug approved by the Food and Drug Administration \[Duavee™, Pfizer, Inc\] for treatment of postmenopausal symptoms (vaginal dryness and hot flashes) and prevention of osteoporosis also improves insulin sensitivity by decreasing body fat especially in your liver. DUAVEE™ (Conjugated Estrogens/Bazedoxifene) is a new prescription medicine that contains a mixture of estrogen (the main female hormone made by the ovaries) and bazedoxifene, which is FDA approved. For over 60 years, estrogens have been used as hormonal treatments to help manage hot flashes and help prevent postmenopausal bone loss. But in the treatment of postmenopausal women, the use of estrogens alone can increase the risk of developing cancer of the uterus. So estrogens have been traditionally paired with a progestin to decrease the risk of hyperplasia (the thickening of the lining of the uterus), which can be a precursor to cancer. DUAVEE™ uses bazedoxifene, a selective estrogen receptor modulator (SERM), in place of a progestin to help protect the uterus against thickening of the uterus that may result from estrogens alone. In this study, you will get either DUAVEE™ or the placebo (a dummy pill that may look like medicine but contains no active medication) first and then switch to the other pill.
Detailed description
This study involves a screening process to see if you are eligible to participate followed by two 8-week treatment periods separated by an 8-week washout period. The two 8-week treatments will be with: 1. 8 weeks of treatment with TSEC (Duavee™, combination of CE and BZA) 2. 8 weeks of treatment with a dummy pill (Placebo) The order of these 2 8-week treatment periods will be decided by chance (coin flip). STUDY VISITS (11 VISITS in total) If you participate in this study, after referral from the Baton Rouge General Obstetrics and Gynecology Physicians, you will complete 1 screening visit at Pennington Biomedical Research Center to determine your eligibility. If you are eligible and enrolled in the study, you will complete an additional 10 visits (8 brief visits and 2 overnight inpatient stays). Please note all times provided for procedures and the total times for each clinic visit are approximations and may vary depending on circumstances. SCREENING VISIT (1 visit, approximately 1.5 hours, fasting): Please do not drink any food or water for 10 hours before this appointment. Participants are asked to report to the Pennington clinic fasting. After a detailed explanation of the whole study by a coordinator, if you agree to the procedures by signing a consent form, you will have: 1. Your height and body weight measured. 2. You will then have an ECG (electrocardiogram) to measure your heart rate and rhythm. 3. Your blood pressure will be measured. 4. A blood sample (\<1 teaspoon) and urine will be collected to assess your general health. 5. You will have a medical history and physical examination. If fully eligible according to the data collected during the screening visit, you will be called to set up a second visit to provide you with the medication or the dummy pill. VISIT 2 (30 minutes): You will come to the Pennington to pick up your drug supply (real medication or dummy pill) and meet with a nurse or a study coordinator to give you instructions on when and how to take your pill once a day. VISITS 3-5 (30 minutes each): At week 1, 3, and 5 of your 8-week treatment period, you will come to our outpatient clinic to measure your weight, blood pressure and pulse, collect some feedback on your health and check your medication compliance as well as distribute new medications. VISIT 6 (24 hours at our inpatient unit): You will be admitted to our inpatient unit at 4pm (not fasted) for measures of: 1. Total body fat by DXA 2. Abdominal visceral fat by Magnetic Resonance Imaging (MRI) 3. Fat in your liver and muscle by Magnetic Resonance Spectroscopy (MRS) You will then receive a standard dinner at \ 7pm and will be ask to switch off the light in your bedroom at \ 10pm The next morning investigators will wake you up at \ 4.45am to start an IV line and start a 8-hour procedure (Euglycemic Clamp) to measure how your body responds to insulin. You will be discharged from the inpatient unit between 2 and 3 pm after being fed a lunch. Visit 1 is Screening; Visit 2/7 is Wk0/17; Visit 3/8 is Wk1/18; Visit 4/9 is Wk3/20; Visit 5/10 is Wk5/22 and Visit 6/11 is Wk8/25 ECG: Screening Vital Signs, Height, Weight, Waist & Hip Measurements: Screening, Visit 3, Visit 4, Visit 5 & Visit 6 Fasting Blood & Urine Sample: Screening and Visit 6 Medical History & Physical Exam + Questionnaire Barriers: Screening Pick up pills/receive instructions: Visit 2, Visit 3, Visit 4, & Visit 5 Health Status/Medication Compliance Visit 3, Visit 4 & Visit 5 Admittance to Inpatient Unit: Visit 6 Body Composition (DXA): Visit 6 Body Composition (MRI): Visit 6 Liver/Muscle Fat (MRS): Visit 6 Euglycemic Clamp with biopsies: Visit 6 Eight weeks later (during which you will not take any pill), you will start the same sequence of visits (VISITS 7-11) as shown above for Visits 2-6 but this time with the other pill. DESCRIPTION OF PROCEDURES Euglycemic IV clamp (8 hours): This procedure measures how the body responds to insulin. Insulin is normally produced by your body during meals and helps your body use sugar. There will be 2 IV lines, one in your arm and one in your hand on the opposite side. Approximately 30 minutes after the IV lines are inserted; investigators will perform a fat biopsy to sample fat cells beneath the skin of your stomach area. Then, a muscle biopsy will be obtained to sample muscle cells beneath the skin of your thigh. Small amounts of glucose and insulin will be infused into your arm. Your blood sugar level will be checked every 5-10 minutes from the IV in your hand to determine how much glucose you should have to keep your blood sugar at a normal level. Your hand will be placed inside a warming box to increase skin temperature to about 105 degrees Fahrenheit. The temperature will be warm, but not uncomfortable. During your IV procedure, a small amount of your own blood (less than 1 teaspoon) will immediately be returned into your vein through the IV after each specimen is collected Three times during the 8-hour procedure, investigators will place a clear plastic hood, through which fresh air flows, over your head to measure how many calories your body burns. This measure will last 40 minutes each time. Your urine will be collected throughout the test in a urine jug (at the end of the test or in 2 collections if necessary). Fat biopsy (about 30 minutes): This procedure is used to sample fat cells from underneath the abdominal skin after cleansing the skin with iodine and using a local anesthetic. After cleansing the area, the doctor or Nurse Practitioner will make a small incision in the skin and introduce a needle under the skin to remove fat cells. About 1 gram (less than half a teaspoon size) of fat will be removed. After the biopsy is completed, the skin will be held closed with a sterile adhesive bandage; an antibiotic ointment will be applied. Risks: Fat Biopsy: Mild to severe pain, soreness, and bruising, and a small scar are common risks. There is a small risk of a hematoma (collection of blood in the tissue) or infection at the biopsy site. Sterile technique will be used to minimize these risks and the biopsy site will be monitored closely. Muscle Biopsy (about 30 minutes): This procedure is used to sample muscle cells from underneath the skin of the leg. After cleaning the skin with iodine and using a local anesthetic, the doctor or nurse practitioner will make a small incision in the skin and introduce a needle under the skin to remove muscle cells. About 200-750 milligrams (less than a teaspoon size) of muscle will be removed. After the biopsy is completed, the skin will be held closed with a sterile adhesive bandage and an antibiotic ointment will be applied. Risks: Muscle Biopsy: Mild to severe pain, soreness, bruising, and a small scar are common risks. A hematoma (collection of blood in the tissue) may occur. There is a slight risk that a superficial nerve may be cut; the nerve may heal, or it may result in a permanent loss of sensation in the skin at the biopsy site. DXA - Whole Body Scan (\ 4 minutes): This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes less than four minutes. This scan is for research purposes only and not for diagnostic treatment. MRI Abdomen (30 minutes): This scan measures the amount of fat in your abdomen. You will change into a hospital gown and remove all objects containing metal from your body. You will lie on your back on the scanner table with your arms above your head. A large coil will be placed around your upper abdomen. You will then be moved into the magnet and will be instructed to hold your breath 4-5 times (once for six seconds, once for 13 seconds, and 2-3 times for about 18 seconds after the upper abdominal scans are completed, you will be moved up on the table, and the coil will be placed over your lower abdomen. The same scans will be acquired over this area with the same 4-5 breath holds. The total scan time for this procedure is approximately 30 minutes. During the scan, you will hear loud tapping noises. You will be given headphones for protection from the scanner noise and can listen to music during the scan if desired. You will also be given a call button should you need the MRI Technician during the exam. This scan is for research purposes only and not for diagnostic treatment. MRS IHL (Intrahepatic lipid) (20-30 minutes): This scan measures the amount of fat in your liver. You will change into a hospital gown and remove all objects containing metal from your body. You will be placed on the scanner table head first and on your stomach. The table will move you into the magnet where data will be obtained. The scan will last for approximately 20-30 minutes. During the scan, you will hear loud tapping noises. You will be given head phones for protection from the scanner noise and can listen to music during the scan if desired. You will also be given a call button should you need the MRI tech during the exam. This scan is for research purposes only and not for diagnostic treatment. MRS IMCL (Intramyocellular lipid) (60 minutes): This scan measures the amount of fat in your muscle fibers. You will change into a hospital gown and remove all objects containing metal from your body. You will lie on your back on the scanner table with the right leg in a special coil. The top part of the coil will then be placed over your calf. Cushions will be inserted around the calf to help keep the leg as still as possible. The table will then move you into the scanner where a series of several scans will be obtained. The entire procedure will last approximately 60 minutes. During the scan, you will hear loud tapping noises. You will be given head phones for protection from the scanner noise and can listen to music during the scan if desired. You will also be given a call button should you need the MRI tech during the exam. This scan is for research purposes only and not for diagnostic treatment.
Interventions
Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
non active
Sponsors
Study design
Eligibility
Inclusion criteria
* Post-menopausal women (\<5y post last period) * Age between 50-60y * Symptomatic (hot flashes, vaginal dryness) or asymptomatic * BMI 30-40 kg/m2 * Normal mammogram past 12 months * Physician clearance (Ob/Gyn or PBRC)
Exclusion criteria
* Amenorrhea other causes (excess androgen) * Diabetes mellitus * Medications: diabetes, antidepressant uncontrolled depression (2 months stability on SSRIs are fine), antipsychotics, oral steroids, weight loss drugs * Tricyclic antidepressants (TCAs) * ≤ 3 month washout of birth control pill, estrogen, and/or progestin * Hysterectomy (total or partial) * Contraindications to estrogen treatment * Unable or unwilling to do an MRS
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of CE/BZA (TSEC) on Body Composition | 8 weeks |
| Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy | 8 weeks |
| Effect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy) | 8 weeks |
| Effect of CE/BZA (TSEC) on Body Mass Index | 8 weeks |
| Effect of CE/BZA (TSEC) on Percent Body Fat | 8 weeks |
| Effect of CE/BZA (TSEC) on Fat Cell Ratio (Small/Large) | 8 weeks |
| Effect of CE/BZA (TSEC) on Mean Fat Cell Size | 8 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect of CE/BZA (TSEC) on Fasting Labs | 8 weeks | — |
| Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Insulin | 8 weeks | Low-Dose Insulin \[20 mIU/min/m2 \] High-Dose Insulin \[120 mIU/min/m2 \] |
| Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) | 8 weeks | Low-Dose Insulin \[20 mIU/min/m2 \], High-Dose Insulin \[120 mIU/min/m2 \] |
| Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFA | 8 weeks | Low-Dose Insulin \[20 mIU/min/m2 \] High-Dose Insulin \[120 mIU/min/m2 \] |
| Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | 8 weeks | — |
| Effect of CE/BZA (TSEC) on Fasting Insulin | 8 weeks | — |
| Effect of CE/BZA (TSEC) on Fasting Free Fatty Acids | 8 weeks | — |
| Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Glucose | 8 weeks | Low-Dose Insulin \[ 20 mIU/min/m2 \] |
Countries
United States
Participant flow
Recruitment details
269 applied to participate. 82 completed a web base screening. 18 screened in the clinic. 10 were ineligible and 8 enrolled and were randomized and completed the study.
Pre-assignment details
the 10 ineligible were 5 BMI out of range. 2 \> 5 year post menopause. 1 because of medication. 1 for medical condition and 1 failed to return to clinic.
Participants by arm
| Arm | Count |
|---|---|
| Enrolled Female Participants This study involves a screening process to see if you are eligible to participate followed by two 8-week treatment periods separated by an 8-week washout period. The two 8-week treatments will be with:
8 weeks of treatment with TSEC (Duavee™, combination of CE and BZA) 8 weeks of treatment with a dummy pill (Placebo) The order of these 2 8-week treatment periods will be decided by chance (coin flip). | 8 |
| Total | 8 |
Baseline characteristics
| Characteristic | Enrolled Female Participants |
|---|---|
| Age, Customized Age 50-60 years | 8 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 6 Participants |
| Region of Enrollment United States | 8 Participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 8 |
| other Total, other adverse events | 7 / 8 | 5 / 8 |
| serious Total, serious adverse events | 0 / 8 | 0 / 8 |
Outcome results
Effect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy)
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy) | Small Fat Cells | 66.4 Percent | Standard Deviation 8.7 |
| Placebo | Effect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy) | Large Fat Cells | 33.6 Percent | Standard Deviation 8.7 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy) | Small Fat Cells | 66.0 Percent | Standard Deviation 5.5 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy) | Large Fat Cells | 34.0 Percent | Standard Deviation 5.5 |
Effect of CE/BZA (TSEC) on Body Composition
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Body Composition | Weight | 91.3 Kilograms | Standard Deviation 6.8 |
| Placebo | Effect of CE/BZA (TSEC) on Body Composition | Fat Mass | 45.5 Kilograms | Standard Deviation 4.6 |
| Placebo | Effect of CE/BZA (TSEC) on Body Composition | Fat-free Mass | 46.0 Kilograms | Standard Deviation 3.5 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Body Composition | Weight | 90.6 Kilograms | Standard Deviation 7.2 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Body Composition | Fat Mass | 45.7 Kilograms | Standard Deviation 4 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Body Composition | Fat-free Mass | 45.5 Kilograms | Standard Deviation 4 |
Effect of CE/BZA (TSEC) on Body Mass Index
Time frame: 8 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Body Mass Index | 36.6 kilograms per meter squared | Standard Deviation 2.7 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Body Mass Index | 36.4 kilograms per meter squared | Standard Deviation 2.9 |
Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy | Tibialis anterior intramyocellular lipid (IMCL) | 0.33 Percent | Standard Deviation 0.23 |
| Placebo | Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy | Tibialis anterior extramyocellular lipid (EMCL) | 1.87 Percent | Standard Deviation 1.6 |
| Placebo | Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy | Intrahepatic Lipid (IHL) | 9.00 Percent | Standard Deviation 13.9 |
| Placebo | Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy | Soleus intramyocellular lipid (IMCL) | 0.29 Percent | Standard Deviation 0.27 |
| Placebo | Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy | Soleus extramyocellular lipid (EMCL) | 0.32 Percent | Standard Deviation 0.28 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy | Soleus extramyocellular lipid (EMCL) | 0.43 Percent | Standard Deviation 0.45 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy | Soleus intramyocellular lipid (IMCL) | 0.36 Percent | Standard Deviation 0.47 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy | Tibialis anterior extramyocellular lipid (EMCL) | 4.13 Percent | Standard Deviation 6.06 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy | Tibialis anterior intramyocellular lipid (IMCL) | 0.69 Percent | Standard Deviation 0.5 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy | Intrahepatic Lipid (IHL) | 8.06 Percent | Standard Deviation 9.14 |
Effect of CE/BZA (TSEC) on Fat Cell Ratio (Small/Large)
Time frame: 8 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Fat Cell Ratio (Small/Large) | 2.19 ratio | Standard Deviation 1 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Fat Cell Ratio (Small/Large) | 2.00 ratio | Standard Deviation 0.45 |
Effect of CE/BZA (TSEC) on Mean Fat Cell Size
Time frame: 8 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Mean Fat Cell Size | 1.35 um^3 (x10^6) | Standard Deviation 0.4 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Mean Fat Cell Size | 1.6 um^3 (x10^6) | Standard Deviation 0.4 |
Effect of CE/BZA (TSEC) on Percent Body Fat
Time frame: 8 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Percent Body Fat | 50.9 percentage of total body weight | Standard Deviation 2.5 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Percent Body Fat | 51.4 percentage of total body weight | Standard Deviation 1.9 |
Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp)
Low-Dose Insulin \[20 mIU/min/m2 \], High-Dose Insulin \[120 mIU/min/m2 \]
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) | Basal SGO | 2.83 mg/min [FFM+17.7] | Standard Deviation 0.41 |
| Placebo | Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) | GDR at Low-Dose Insulin | 2.48 mg/min [FFM+17.7] | Standard Deviation 0.91 |
| Placebo | Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) | GDR at High-Dose Insulin | 11.99 mg/min [FFM+17.7] | Standard Deviation 4.49 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) | Basal SGO | 2.68 mg/min [FFM+17.7] | Standard Deviation 0.32 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) | GDR at Low-Dose Insulin | 2.55 mg/min [FFM+17.7] | Standard Deviation 1.04 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) | GDR at High-Dose Insulin | 11.68 mg/min [FFM+17.7] | Standard Deviation 4.23 |
Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Glucose
Low-Dose Insulin \[ 20 mIU/min/m2 \]
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Glucose | Low-Dose Glucose | 90 mg/dL | Standard Deviation 1 |
| Placebo | Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Glucose | High-Dose Glucose | 97 mg/dL | Standard Deviation 3 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Glucose | Low-Dose Glucose | 88 mg/dL | Standard Deviation 1 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Glucose | High-Dose Glucose | 95 mg/dL | Standard Deviation 3 |
Effect of CE/BZA (TSEC) on Fasting Free Fatty Acids
Time frame: 8 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Fasting Free Fatty Acids | 0.72 mmol/L | Standard Deviation 0.06 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Fasting Free Fatty Acids | 0.78 mmol/L | Standard Deviation 0.06 |
Effect of CE/BZA (TSEC) on Fasting Insulin
Time frame: 8 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Fasting Insulin | 16.6 uU/mL | Standard Deviation 2.8 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Fasting Insulin | 15.7 uU/mL | Standard Deviation 2.8 |
Effect of CE/BZA (TSEC) on Fasting Labs
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Fasting Labs | Total cholesterol | 179 Milligrams/deciliter | Standard Deviation 34 |
| Placebo | Effect of CE/BZA (TSEC) on Fasting Labs | HDL-cholesterol | 51 Milligrams/deciliter | Standard Deviation 11 |
| Placebo | Effect of CE/BZA (TSEC) on Fasting Labs | Triglycerides | 138 Milligrams/deciliter | Standard Deviation 75 |
| Placebo | Effect of CE/BZA (TSEC) on Fasting Labs | LDL-cholesterol | 100 Milligrams/deciliter | Standard Deviation 24 |
| Placebo | Effect of CE/BZA (TSEC) on Fasting Labs | Glucose | 105 Milligrams/deciliter | Standard Deviation 4 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Fasting Labs | LDL-cholesterol | 99 Milligrams/deciliter | Standard Deviation 20 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Fasting Labs | Glucose | 102 Milligrams/deciliter | Standard Deviation 4 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Fasting Labs | Total cholesterol | 187 Milligrams/deciliter | Standard Deviation 32 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Fasting Labs | Triglycerides | 156 Milligrams/deciliter | Standard Deviation 73 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Fasting Labs | HDL-cholesterol | 57 Milligrams/deciliter | Standard Deviation 14 |
Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFA
Low-Dose Insulin \[20 mIU/min/m2 \] High-Dose Insulin \[120 mIU/min/m2 \]
Time frame: 8 weeks
Population: No data reported for FFA for High-Dose Insulin
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFA | Free Fatty Acids (FFA) at Low-Dose Insulin | 0.13 mmol/L | Standard Deviation 0.05 |
| Placebo | Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFA | Free Fatty Acids (FFA) at High-Dose Insulin | 0 mmol/L | Standard Deviation 0 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFA | Free Fatty Acids (FFA) at Low-Dose Insulin | 0.13 mmol/L | Standard Deviation 0.05 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFA | Free Fatty Acids (FFA) at High-Dose Insulin | 0 mmol/L | Standard Deviation 0 |
Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Insulin
Low-Dose Insulin \[20 mIU/min/m2 \] High-Dose Insulin \[120 mIU/min/m2 \]
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Insulin | Insulin at Low-Dose Insulin | 37.8 uU/mL | Standard Deviation 2.4 |
| Placebo | Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Insulin | Insulin at High-Dose Insulin | 250.8 uU/mL | Standard Deviation 19.3 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Insulin | Insulin at High-Dose Insulin | 259.8 uU/mL | Standard Deviation 19.3 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Insulin | Insulin at Low-Dose Insulin | 34.8 uU/mL | Standard Deviation 2.4 |
Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)
Low-Dose Insulin \[20 mIU/min/m2 \], High-Dose Insulin \[120 mIU/min/m2 \]
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Respiratory Quotient (RQ) at Basal | 0.81 unitless | Standard Deviation 0.03 |
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Respiratory Quotient (RQ) at Low-Dose | 0.85 unitless | Standard Deviation 0.04 |
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Respiratory Quotient (RQ) at Hight-Dose | 0.92 unitless | Standard Deviation 0.05 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Respiratory Quotient (RQ) at Hight-Dose | 0.91 unitless | Standard Deviation 0.06 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Respiratory Quotient (RQ) at Basal | 0.80 unitless | Standard Deviation 0.03 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Respiratory Quotient (RQ) at Low-Dose | 0.83 unitless | Standard Deviation 0.03 |
Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)
Low-Dose Insulin \[20 mIU/min/m2 \], High-Dose Insulin \[120 mIU/min/m2 \]
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Oxidation at Basal | 1.2 mg/min/[FFM+17.7] | Standard Deviation 0.1 |
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Storage at Basal | 1.6 mg/min/[FFM+17.7] | Standard Deviation 0.3 |
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Oxidation at Low-Dose | 1.6 mg/min/[FFM+17.7] | Standard Deviation 0.1 |
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Storage at Low-dose | 0.9 mg/min/[FFM+17.7] | Standard Deviation 0.3 |
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Oxidation at High-Dose | 2.7 mg/min/[FFM+17.7] | Standard Deviation 0.3 |
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Storage at High-Dose | 9.3 mg/min/[FFM+17.7] | Standard Deviation 1.4 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Oxidation at High-Dose | 2.7 mg/min/[FFM+17.7] | Standard Deviation 0.3 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Oxidation at Basal | 1.0 mg/min/[FFM+17.7] | Standard Deviation 0.1 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Storage at Low-dose | 1.2 mg/min/[FFM+17.7] | Standard Deviation 0.3 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Storage at Basal | 1.6 mg/min/[FFM+17.7] | Standard Deviation 0.3 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Storage at High-Dose | 9.0 mg/min/[FFM+17.7] | Standard Deviation 1.4 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Carbohydrate Oxidation at Low-Dose | 1.3 mg/min/[FFM+17.7] | Standard Deviation 0.1 |
Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)
Time frame: 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Resting Metabolic Rate (RMR) on Basal | 1410 kcal/day | Standard Deviation 126 |
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Resting Metabolic Rate (RMR) on Low-Dose Insulin | 1379 kcal/day | Standard Deviation 94 |
| Placebo | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Resting Metabolic Rate (RMR) on High-Dose Insulin | 1516 kcal/day | Standard Deviation 113 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Resting Metabolic Rate (RMR) on Low-Dose Insulin | 1378 kcal/day | Standard Deviation 137 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Resting Metabolic Rate (RMR) on Basal | 1471 kcal/day | Standard Deviation 161 |
| TSEC (Duavee™, Combination of CE and BZA) | Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry) | Resting Metabolic Rate (RMR) on High-Dose Insulin | 1576 kcal/day | Standard Deviation 83 |